Anti-IL-17 phase II data for psoriasis: A review (Q30760301)

26 June 2017

title

Anti-IL-17 phase II data for psoriasis: A review (English)

1 reference

26 June 2017

Gabrielle Brown

1 reference

26 June 2017

Mona Malakouti

1 reference

26 June 2017

Eva Wang

1 reference

26 June 2017

John Y Koo

1 reference

26 June 2017

Ethan Levin

1 reference

26 June 2017

publication date

20 February 2014

1 reference

Journal of Dermatological Treatment

26 June 2017

published in

1 reference

26 June 2017

1 reference

26 June 2017

1 reference

26 June 2017

page(s)

32-36

1 reference

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Infliximab: efficacy in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Cytokine-based therapy in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

gammadelta T cells: an important source of IL-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Circulating Th17, Th22, and Th1 cells are increased in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Structure and signalling in the IL-17 receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

IL-17A inhibits the expansion of IL-17A-producing T cells in mice through "short-loop" inhibition via IL-17 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

IL-17A controls IL-17F production and maintains blood neutrophil counts in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Cardiovascular Risk and Psoriasis: the Role of Biologic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

The Th17/Treg imbalance in patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

IL-17 receptor and its functional significance in psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Role of IL-17 in psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.878448

10.3109/09546634.2013.878448

21 January 2018

Identifiers

DOI

1 reference

26 June 2017

1 reference